



08-51-51

Patent Application
Attorney Docket No. PC1038 A

RECEIVED
TECH CENTER 1600/2900
AUG 3 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: HUATAN, ET AL.

APPLICATION NO.: 09/813,340

Examiner: Not Yet Assigned

FILING DATE: March 20, 2001

Group Art Unit: Not Yet Assigned

TITLE: ORAL FORMULATIONS OF
MEDICAMENTS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: July 31, 2001

Pfizer Inc.
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 573-2030

Lorraine B. Ling
Lorraine B. Ling
Attorney for Applicant(s)
Reg. No. 35,251